Melola Discovery

← Melola Discovery

Akses terbuka Jurnal Tanpa peringkat SINTA

Review Article: Pharmacology GS-441524, Source, Pharmacodynamics, Pharmacokinetics, And Efficacy in Treatment of Feline Infectious Peritonitis

Jurnal Riset Veteriner Indonesia (Journal of The Indonesian Veterinary Research) · Vol. UME No. 1 (2026)

DOI
10.20956/jrvi.v10i1.48183
ISSN
2615-2835, 2614-0187
Terbit
2026-06-30
Penerbit
Hasanuddin University
Bahasa
en
Lisensi
creativecommons.org/licenses/by-nc/4.0

Abstrak

Feline infectious peritonitis (FIP) is a historically fatal disease caused by a virulent mutation of feline coronavirus, characterized by systemic inflammation, immune dysregulation, and high mortality in untreated cats. The emergence of GS-441524, an adenosine nucleoside analog targeting viral RNA-dependent RNA polymerase (RdRp), has transformed the therapeutic outlook for FIP and represents a significant shift from palliative management to effective antiviral intervention. This review aims to synthesize current evidence on the pharmacology, therapeutic efficacy, safety, accessibility, and regulatory considerations surrounding GS-441524, while identifying remaining knowledge gaps and priorities for future research. GS-441524 demonstrates favorable pharmacokinetic and pharmacodynamic properties, including efficient cellular activation, strong antiviral potency, and adequate tissue distribution, with high clinical success rates across effusive, non-effusive, ocular, and neurological forms of FIP. Its safety profile is generally acceptable, though injection-site reactions, limited penetration into protected compartments, and variability in unregulated formulations present ongoing challenges. Regulatory inaccessibility remains a major barrier in many countries, driving reliance on black-market products and underscoring the need for evidence-based veterinary approval pathways. Overall, GS-441524 represents a highly effective antiviral agent with substantial potential to redefine FIP treatment standards. Continued research is needed to clarify resistance mechanisms, optimize dosing strategies, improve pharmaceutical standardization, and advance regulatory acceptance to ensure safe, reliable, and equitable access for feline patients.

Jaringan kolaborasi para penulis

Belum ada rekan penulis di Melola.

Sumber metadata: OAI-PMH (metadata jurnal) https://journal.unhas.ac.id/index.php/jrvi/oai, pertama di-harvest 3 Nov 2026, terakhir terlihat 15 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Review Article : Pharmacology GS-441524, Source, Pharmacodynamics, Pharmacokinetics, And Efficacy in Treatment of Feline Infectious Peritonitis</dc:title>
	<dc:creator xml:lang="en">nurjannah, ismi</dc:creator>
	<dc:description xml:lang="en">Feline infectious peritonitis (FIP) is a historically fatal disease caused by a virulent mutation of feline coronavirus, characterized by systemic inflammation, immune dysregulation, and high mortality in untreated cats. The emergence of GS-441524, an adenosine nucleoside analog targeting viral RNA-dependent RNA polymerase (RdRp), has transformed the therapeutic outlook for FIP and represents a significant shift from palliative management to effective antiviral intervention. This review aims to synthesize current evidence on the pharmacology, therapeutic efficacy, safety, accessibility, and regulatory considerations surrounding GS-441524, while identifying remaining knowledge gaps and priorities for future research. GS-441524 demonstrates favorable pharmacokinetic and pharmacodynamic properties, including efficient cellular activation, strong antiviral potency, and adequate tissue distribution, with high clinical success rates across effusive, non-effusive, ocular, and neurological forms of FIP. Its safety profile is generally acceptable, though injection-site reactions, limited penetration into protected compartments, and variability in unregulated formulations present ongoing challenges. Regulatory inaccessibility remains a major barrier in many countries, driving reliance on black-market products and underscoring the need for evidence-based veterinary approval pathways. Overall, GS-441524 represents a highly effective antiviral agent with substantial potential to redefine FIP treatment standards. Continued research is needed to clarify resistance mechanisms, optimize dosing strategies, improve pharmaceutical standardization, and advance regulatory acceptance to ensure safe, reliable, and equitable access for feline patients.</dc:description>
	<dc:publisher xml:lang="en">Hasanuddin University</dc:publisher>
	<dc:date>2026-06-30</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://journal.unhas.ac.id/index.php/jrvi/article/view/48183</dc:identifier>
	<dc:identifier>10.20956/jrvi.v10i1.48183</dc:identifier>
	<dc:source xml:lang="en">Jurnal Riset Veteriner Indonesia (Journal of The Indonesian Veterinary Research); VOLUME 10, No 1, JANUARY 2026</dc:source>
	<dc:source>2615-2835</dc:source>
	<dc:source>2614-0187</dc:source>
	<dc:source>10.20956/jrvi.v10i1</dc:source>
	<dc:language>en</dc:language>
	<dc:relation>https://journal.unhas.ac.id/index.php/jrvi/article/view/48183/14660</dc:relation>
	<dc:rights xml:lang="en">http://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>